Gil Mira, María del MarNicolaides, Kypros H.2020-10-142020-10-1420191863-5490http://hdl.handle.net/10641/2005Several externally blinded validation and implementation studies in the last 9 years have shown that it is now possible, through analysis of cell-free (cf) DNA in maternal blood, to effectively detect a high proportion of fetuses affected by trisomies 21, 18, and 13 at a much lower false-positive rate (FPR) than all other existing screening methods. This article is aimed at reviewing technical and clinical considerations for implementing cfDNA testing in routine practice, including methods of analysis, performance of the test, models for clinical implementation, and interpretation of results.engAtribución-NoComercial-SinDerivadas 3.0 Españahttp://creativecommons.org/licenses/by-nc-nd/3.0/es/Cell-free DNANon-invasive prenatal testingTrisomiesPrenatal screeningAneuploidiesjournal articleopen access10.1007/s11825-019-00265-4